US Approves AstraZeneca’s Zurampic Gout Drug

Swedish drugmaker AstraZeneca has gained approval from the US Food and Drug Administration (FDA) to market Zurampic, a treatment for gout, the debilitating form of inflammatory arthritis caused by raised levels of uric acid, or hyperuricemia, in the blood.

Zurampic works by inhibiting the urate transporter responsible for the majority of the renal reabsorption of uric acid. It has been approved in combination with a xanthine oxidase inhibitor (XOI) for treating hyperuricemia in patients who have not managed to reduce their uric acid levels with an XOI alone.

When used with XOIs allopurinol or febuxostat, the therapy is said to provide a dual mechanism to increase excretion and decrease production of uric acid, enabling more patients with inadequately controlled gout to reach their treatment goals.

The FDA approval is based on data from three phase III studies. Lawrence Edwards, chairman and CEO of the Gout and Uric Acid Education Society, said a new approach to treating the disease is long overdue as there has been limited therapy innovation over the last 50 years.

Zurampic is also under review in the EU as well as other undisclosed territories. On Dec. 18, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the drug’s authorisation.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.